<p>Bluejay Diagnostics (BJDX) 的股票在週二經歷了極大的上漲，此前這家醫療診斷公司與 Argonaut Manufacturing Services 簽署了一項協議。兩家公司達成了戰略合作伙伴關係，Argonaut Manufacturing Services 將支持 Bluejay Diagnostics 的 Symphony 平台的開發。Symphony 是一個用於膿毒症分診和疾病進展監測的檢測系統。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖可信賴的數據驅動投資工具，使用 TipRanks Premium，從分析師評級和預測到突發新聞和投資組合分析。</li>
<li>通過 TipRanks 智能投資者通訊發現高信念股票推薦和新的投資機會。</li>
</ul>
<p>Bluejay Diagnostics 指出，這項協議旨在擴大其在美國的製造能力。公司希望這將增強其未來的商業基礎設施並提升供應鏈的韌性。這樣做將有助於防止公司受到關税和國際貿易影響。這對 Bluejay Diagnostics 來説是一個重大變化，因為該公司在很大程度上依賴海外製造。</p>
<p>Bluejay Diagnostics 的總裁兼首席執行官 Neil Dey 對與 Argonaut Manufacturing Services 的戰略合作伙伴關係表示滿意。他表示，這 &#34;反映了我們在朝着關鍵商業里程碑邁進時，建立可擴展和以質量為中心的運營基礎的承諾。&#34;</p>
<h2><strong>Bluejay Diagnostics 今日股票動態</strong></h2>
<p>Bluejay Diagnostics 的股票在週二的盤前交易中上漲了 184.33%，此前在週一上漲了 1.4%。然而，該股票年初至今下跌了 18.67%，過去 12 個月下跌了 69.52%。</p>
<p>今天 BJDX 股票的交易活動強勁，約有 3300 萬股易手。相比之下，該公司的三個月平均日交易量約為 527 萬股。</p>
<h2><strong>Bluejay Diagnostics 股票是買入、賣出還是持有？</strong></h2>
<p>轉向華爾街，傳統分析師對 Bluejay Diagnostics 股票的覆蓋不足。幸運的是，TipRanks 的 AI 分析師 Spark 對此進行了覆蓋。Spark 將 BJDX 股票評級為中性，目標價為 1.50 美元。它將 &#34;非常疲弱的財務表現（收入微薄、持續虧損和持續現金消耗）&#34; 作為這一立場的理由。</p>

BJDX

<p>Bluejay Diagnostics (BJDX) 的股票在盤前交易中上漲超過 184%，原因是與 Argonaut Manufacturing Services 簽署了戰略合作伙伴關係。該協議旨在擴大其 Symphony 敗血症檢測平台在美國的製造能力，增強供應鏈的韌性，並減少對海外生產的依賴。儘管股價上漲，BJDX 今年迄今為止和過去一年仍大幅下跌。TipRanks 的 AI 分析師 Spark 將該股票評級為中性，目標價為 1.50 美元，理由是財務表現疲弱</p>

<p>Bluejay Diagnostics (BJDX) stock underwent an extreme rally on Tuesday after the medical diagnostics company signed an agreement with Argonaut Manufacturing Services. The two companies have agreed to a strategic partnership that will see Argonaut Manufacturing Services support the development of Bluejay Diagnostics' Symphony platform. Symphony is a testing system for sepsis triage and monitoring of disease progression.</p>
<div class="lb-trans"><p>Bluejay Diagnostics (BJDX) 的股票在週二經歷了極大的上漲，此前這家醫療診斷公司與 Argonaut Manufacturing Services 簽署了一項協議。兩家公司達成了戰略合作伙伴關係，Argonaut Manufacturing Services 將支持 Bluejay Diagnostics 的 Symphony 平台的開發。Symphony 是一個用於膿毒症分診和疾病進展監測的檢測系統。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.</li>
<li>Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖可信賴的數據驅動投資工具，使用 TipRanks Premium，從分析師評級和預測到突發新聞和投資組合分析。</li>
<li>通過 TipRanks 智能投資者通訊發現高信念股票推薦和新的投資機會。</li>
</ul>
</div><p>Bluejay Diagnostics noted that this agreement is designed to expand its U.S. manufacturing capabilities. The company hopes that this will strengthen its future commercial infrastructure and enhance supply chain resilience. Doing so would help prevent the company from having to deal with the effects of tariffs and international trade. This would be a major change for Bluejay Diagnostics, which largely relies on overseas manufacturing.</p>
<div class="lb-trans"><p>Bluejay Diagnostics 指出，這項協議旨在擴大其在美國的製造能力。公司希望這將增強其未來的商業基礎設施並提升供應鏈的韌性。這樣做將有助於防止公司受到關税和國際貿易影響。這對 Bluejay Diagnostics 來説是一個重大變化，因為該公司在很大程度上依賴海外製造。</p>
</div><p>Neil Dey, president and CEO of Bluejay Diagnostics, was pleased with the strategic partnership with Argonaut Manufacturing Services. He said it &#34;reflects our commitment to building a scalable and quality-focused operational foundation as we progress toward key commercial milestones.&#34;</p>
<div class="lb-trans"><p>Bluejay Diagnostics 的總裁兼首席執行官 Neil Dey 對與 Argonaut Manufacturing Services 的戰略合作伙伴關係表示滿意。他表示，這 &#34;反映了我們在朝着關鍵商業里程碑邁進時，建立可擴展和以質量為中心的運營基礎的承諾。&#34;</p>
</div><h2><strong>Bluejay Diagnostics Stock Movement Today</strong></h2>
<div class="lb-trans"><h2><strong>Bluejay Diagnostics 今日股票動態</strong></h2>
</div><p>Bluejay Diagnostics stock was up 184.33% in premarket trading on Tuesday, following a 1.4% rally yesterday. However, the stock has fallen 18.67% year-to-date and 69.52% over the past 12 months.</p>
<div class="lb-trans"><p>Bluejay Diagnostics 的股票在週二的盤前交易中上漲了 184.33%，此前在週一上漲了 1.4%。然而，該股票年初至今下跌了 18.67%，過去 12 個月下跌了 69.52%。</p>
</div><p>BJDX stock trading activity today was strong, as some 33 million shares changed hands. For comparison, the company's three-month average daily trading volume was about 5.27 million shares.</p>
<div class="lb-trans"><p>今天 BJDX 股票的交易活動強勁，約有 3300 萬股易手。相比之下，該公司的三個月平均日交易量約為 527 萬股。</p>
</div><h2><strong>Is Bluejay Diagnostics Stock a Buy, Sell, or Hold?</strong></h2>
<div class="lb-trans"><h2><strong>Bluejay Diagnostics 股票是買入、賣出還是持有？</strong></h2>
</div><p>Turning to Wall Street, traditional analyst coverage of Bluejay Diagnostics stock is lacking. Fortunately, TipRanks' AI analyst Spark has it covered. Spark rates BJDX stock as Neutral with a $1.50 price target. It cites &#34;very weak financial performance (minimal revenue, ongoing losses, and persistent cash burn)&#34; as reasons for this stance.</p>
<div class="lb-trans"><p>轉向華爾街，傳統分析師對 Bluejay Diagnostics 股票的覆蓋不足。幸運的是，TipRanks 的 AI 分析師 Spark 對此進行了覆蓋。Spark 將 BJDX 股票評級為中性，目標價為 1.50 美元。它將 &#34;非常疲弱的財務表現（收入微薄、持續虧損和持續現金消耗）&#34; 作為這一立場的理由。</p>
</div>

為什麼便士股 Bluejay Diagnostics（BJDX）今天上漲？